NEW YORK, Aug. 07, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies Inc. (Nasdaq:TYME), a clinical stage biotechnology company developing cancer therapeutics to address multiple tumor types, today announced that Steve Hoffman, Co-Founder, Chief Executive and Chief Science Officer and Michael Demurjian, Co-Founder and Chief Operating Officer, will ring the Nasdaq stock market opening bell on Tuesday, August 8, 2017, in celebration of the Company’s recent listing on Nasdaq.
“We are excited to celebrate our recently completed listing on the Nasdaq Capital Market, one of the world’s largest trading platforms,” said Michael Demurjian, Chief Operating Officer. “This is an important event for the Company as we advance our development program to address unmet needs in the fields of oncology.”
A live webcast of the ceremony will be available at https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx from approximately 9:15 a.m. to 9:30 a.m. EDT.
About Tyme
Tyme Inc. is a clinical-stage biopharmaceutical company focused on development and commercialization of highly targeted cancer therapeutics with a broad range of oncology indications. Its lead investigational candidate, SM-88, is a novel first-in-class therapy that is designed to use cancer’s unusual metabolism to selectively break down the cellular defenses of tumors, leading to tumor cell death. Through clinical trials and expanded access programs, SM-88 has been used in over 84 individuals and shown a clinical response in thirteen cancer types. In its first-in-human trial for end-stage, metastatic cancer patients, SM-88 treatment resulted in a median overall survival of 26 months, with 32% of patients alive at the end of the three-year evaluation period without any drug-related serious adverse events. The Company is currently conducting a Phase II trial in prostate cancer in addition to ongoing collaborations with the Mayo Clinic, Mount Sinai and other institutions. For more information, visit our website: www.tymeinc.com.